Emily Low

Emily Low is a Senior Scientist and Project Co-Lead at Nurix Therapeutics, responsible for coordinating activities across various scientific disciplines in an early discovery collaboration project aimed at developing an oral degrader for autoimmunity. Previous roles include Scientist II and Scientist I, where Emily developed methods for identifying E3 ligase targets and produced proteins for key project milestones, respectively. Emily's research experience includes postdoctoral work at Harvard Medical School, focusing on CRL2Lrr1 activity, and graduate research identifying CRL2Lrr1 as a regulator of replication termination. Additionally, Emily has contributed to undergraduate research at the University of California, Berkeley, investigating a protease in magnetotactic bacteria. Academic credentials include a Ph.D. in Biological and Biomedical Sciences from Harvard University and a degree in Molecular and Cell Biology from the University of California, Berkeley.